Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous gp96 immunotherapy in gastric cancer
NCT02317471Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vitespen in gastric cancer (GC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Disease Free Survival at 2 years and Number of participants with adverse events related to gp96 immunotherapy. Status: unknown.
02
Drugs
vitespen
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02317471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317471.